Cboe BZX
01:23:41 2024-04-26 pm EDT
5-day change
1st Jan Change
8.495
USD
-1.34%
-9.20%
-9.15%
Surrozen, Inc.'s Equity Buyback announced on December 15, 2022, has closed with 1,310,496 shares, for $2.7 million.
The company closed its plan on December 15, 2022.
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 10
CI
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing
Apr. 08
MT
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc.
Apr. 03
CI
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis
Apr. 01
CI
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding
Mar. 31
CI
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer
Feb. 07
CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon
Jan. 18
MT
Sector Update: Health Care Stocks Weaker Thursday Afternoon
Jan. 18
MT
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall
Jan. 18
MT
Surrozen, Inc. Provides Corporate Update on Clinical Programs
Jan. 18
CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 08
CI
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis
Nov. 08
CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-09
CI
Surrozen, Inc. Announces Management Changes
23-07-19
CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Index
23-06-23
CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Value Index
23-06-23
CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Value Index
23-06-23
CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Index
23-06-23
CI
Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-10
CI
Surrozen, Inc. Announces Appointment of Eric Bjerkholt to its Board
23-04-05
CI
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-22
CI
Transcript : Surrozen, Inc., Q4 2022 Earnings Call, Mar 22, 2023
23-03-22
Transcript : Surrozen, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 07:30 AM
23-01-12
Top Premarket Decliners
22-12-27
MT
Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower
22-12-15
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the bodyâs response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.
More about the company
Last Close Price
8.61
USD
Average target price
33
USD
Spread / Average Target
+283.28%
Consensus
1st Jan change
Capi.
-9.15% 27.54M +1.84% 42.59B +8.26% 40.65B +49.22% 40.57B -12.36% 26.77B +9.49% 24.81B -24.08% 18.17B +28.83% 12.05B -3.13% 11.7B +7.09% 11.1B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SURROZEN, INC. 
